Increased Expression of SLC25A18 is Associated with Alzheimer’s Disease and is Involved in Aβ42-induced Mitochondrial Dysfunction and Apoptosis in Neuronal Cells

Jia-Yi Song,Yong Jia,Hao Han,Xue-Han Yang,Jing Zhang,Qiang Zhang,Su-Shan Wang,Chun-Yan Wang,Li Chen,Ming Zhang
DOI: https://doi.org/10.1016/j.mito.2024.101918
IF: 4.534
2024-01-01
Mitochondrion
Abstract:Alzheimer’s disease (AD) is currently one of the most serious public health concerns in the world. However, the best approach to treat AD has yet to be discovered, implying that we must continue to work hard to find new AD target genes. In this study, we further analysed Gene Expression Omnibus (GEO) data and discovered that the expression of the Mitochondria glutamate carrier SLC25A18 is associated with AD by screening the differentially expressed genes in different regions of the brains of Alzheimer’s disease patients. To verify the expression of SLC25A18 during Alzheimer’s disease development, we analysed animal models (5×FAD transgenic AD animal model, chemically induced AD animal model, natural ageing animal model), and the results showed that the expression of SLC25A18 was increased in animal models of AD. Further investigation of the different regions found that SLC25A18 expression was elevated in the EC, TeA, and CA3, and expressed in neurons. Next, We found that Aβ42 treatment elevated SLC25A18 expression in Neuro 2A cells. Reducing SLC25A18 expression attenuated mitochondrial dysfunction and neuronal apoptosis caused by Aβ42. Overexpression of SLC25A18 increased ATP and intracellular superoxide anions but decreased mitochondrial membrane potential. The results indicate that SLC25A18 affects mitochondrial function and neuronal apoptosis, and is related to AD, which makes it a potential target for treating brain dysfunction.
What problem does this paper attempt to address?